Quantcast
Last updated on April 18, 2014 at 5:30 EDT

Latest Exelixis Inc. Stories

2014-03-24 12:25:44

Editor Note: For more information about this release, please scroll to bottom. LONDON, March 24, 2014 /PRNewswire/ -- On Friday, March 20, 2014, the NASDAQ Composite ended at 4,276.79, down 0.98%, the Dow Jones Industrial Average fell by 0.17% to close at 16,302.77, and the S&P 500 finished at 1,866.52, down 0.29%. Four out of ten sectors ended the session in negative. During the session gains in the Utilities, Materials and Energy sectors positively impacted the broader...

2013-08-12 08:29:04

Editor Note: For more information about this release, please scroll to bottom NEW YORK, August 12, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Exelixis, Inc. (NASDAQ: EXEL), Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), Puma Biotechnology, Inc. (NYSE: PBYI), and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Today's readers may access these reports free of charge - including full price...

2012-08-10 02:24:53

VANCOUVER, British Columbia, Aug. 10, 2012 /PRNewswire-Asia/ -- EarningForecast.com has issued consensus earnings forecast reports and Equity Research for the following companies: Sprint Nextel (NYSE:S), Cisco (NASDAQ:CSCO), News Corporation (NASDAQ:NWSA), Exelixis (NASDAQ:EXEL), Windstream (NASDAQ:WIN), and Intel (NASDAQ:INTC). (Logo: http://photos.prnewswire.com/prnh/20120809/HK54890LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link...

2012-08-10 02:24:41

VANCOUVER, British Columbia, Aug. 10, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Exelixis (NASDAQ:EXEL), Monster Beverage (NASDAQ:MNST), Delta Air Lines (NYSE:DAL), Robbins & Myers (NYSE:RBN), NRG Energy (NYSE:NRG), and CONSOL Energy (NYSE:CNX). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full...

2009-09-08 09:07:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Small Molecule Kinase Inhibitors http://www.reportlinker.com/p0131227/Small-Molecule-Kinase-Inhibitors.html This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others. Annual forecasts are provided for the...

2008-11-06 06:00:21

Exelixis, Inc. (Nasdaq:EXEL) today announced that it has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) to discover novel therapies targeted against the Liver X Receptor (LXR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. The collaboration, originally established in January of 2006 for a period of two years, was extended in 2007, at Bristol-Myers Squibb's request, through...

2008-10-23 06:00:11

Exelixis, Inc. (Nasdaq:EXEL) today reported preliminary phase 1 data from a dose-escalation trial of XL228 in patients with advanced malignancies (solid tumors, lymphoma, or multiple myeloma) for which standard therapies are no longer effective. XL228 is a potent small molecule inhibitor of insulin-like growth factor type 1 receptor (IGF1R) and SRC, which are protein kinases known to promote cancer cell survival, proliferation, and migration. XL228 also inhibits BCR-ABL, a protein kinase...

2008-10-23 06:00:11

Exelixis, Inc. (Nasdaq:EXEL) today announced that GlaxoSmithKline (GSK) (LSE: GSK; NYSE: GSK) has decided not to exercise its option to license XL184. GSK also informed Exelixis that it had decided not to license the earlier compounds in the collaboration, including XL281, XL228, XL820, and XL844. As a result, Exelixis retains the rights to develop, commercialize, and/or license all of the compounds, subject to payment to GSK of a 3% royalty on net sales of any product incorporating XL184....

2008-10-22 06:00:08

Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL765, a novel small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The trial is being carried out in patients with metastatic or unresectable solid tumors for which known effective measures do not exist or are no longer effective. Dr. Ben Markman, Medical Oncologist, Vall D'Hebron University...

2008-10-22 06:00:08

Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL147, a novel small molecule inhibitor of phosphoinositide-3 kinase (PI3K), which is implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The trial is enrolling patients with metastatic or unresectable solid tumors for which known effective measures do not exist or are no longer effective. The trial is being conducted at Vall D'Hebron University...